U-M was recently ranked No. 9 among institutions globally in cancer research, according to the U.S. News & World Report 2021 Best Global University Rankings.
The detection of DDIT3 rearrangements can be useful in diagnosing myxoid liposarcoma – including uncommon histologic variants – and in distinguishing this sarcoma from other mesenchymal tumors that may be considered in the differential diagnosis.
Michigan Medicine named The Best and Brightest Companies to Work For®. A competition that identifies and honors organizations that display a commitment to excellence in their human resource practices and employee enrichment.
In an effort to ensure the safety of our faculty and staff, while maintaining service excellence for our clients and mutual patients, Michigan Medicine Laboratories (MLabs) has updated our tissue submission requirements.
We have changed our location for COVID testing to an inside drive through to Huron Valley Ambulance Center (HVA).
We are pleased to welcome Dr. Evan Farkash as the new section chief for Renal Pathology as of September 1, 2020.
MLabs is now offering PDL-1 testing for Metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
The Department Pathology and Michigan Medicine Laboratories is pleased to announce and welcome Dr. Liron Pantanowitz, our new A. James French Professor and Director of Anatomic Pathology.
NOW AVAILABLE: NGS Myeloid Panel! MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.
Michigan Medicine has earned the No. 15 spot in Newsweek’s 2020 World’s Best Hospitals list.
The institution also came in fifth in the United States and was named top hospital in Michigan.